WiredEN
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
🇺🇸 United States / English
The world, in perspective.
Fresh headlines from around the world. Gaming, politics, technology and everything in between.
The New York TimesEN
Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.
Ars TechnicaEN
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Markers released top-line results today after previously reporting the trial succeeded.
Allnira republishes accessible articles under owner-declared permissions, with original authors, publishers and image credits. Automatic cloud imports run hourly; open pages check for updates every 15 seconds. Publication delays depend on each feed.